Bulk Pharmaceutical API Sources for mazindol

Bulk Pharmaceutical API Sources for mazindol

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		M2017_SIGMA
NovoSeek		4020
ISpharm		I06-0844
ABI Chem		AC1L1H8E
ChemMol		30102264
ChemMol		49401134

Bulk Active Pharmaceutical Ingredient (API) Sources for Mazindol: Market Overview and Supply Dynamics

Last updated: July 28, 2025

Introduction

Mazindol is a potent anorexigenic compound initially developed in the 1970s as a therapeutic agent for weight management and obesity. Classified as an indanyl-piperazine derivative, mazindol functions primarily as a norepinephrine reuptake inhibitor (NRI), with additional serotonergic activity, contributing to appetite suppression. Although its clinical use diminished in many regions through the 1980s, mazindol remains relevant in niche research contexts and some off-label applications.

The supply chain for mazindol’s API is characterized by a limited number of reputable bulk manufacturers, with recent market dynamics influenced by regulatory concerns, patent status, and the broader pharmaceutical raw material landscape. This report evaluates the current sources of mazindol API, analyzing core suppliers, regional production trends, and quality considerations critical for pharmaceutical development and compounding.

---

Regulatory & Market Context

Since mazindol's original approval, the regulatory environment has shifted—particularly in the U.S. and European markets—limiting its widespread prescription due to safety concerns and off-label use control. Consequently, many established manufacturers have either ceased production or transitioned focus toward other active ingredients. The waning demand has affected API manufacturing volumes, leading to a relatively concentrated supplier landscape.

Despite these factors, specialized pharmaceutical ingredient providers continue to supply mazindol API, often catering to research, analytical, or compounded medication sectors. The global API market’s restructuring promotes reliance on a handful of licensed, GMP-compliant API producers, which impacts procurement strategies.

---

Major Sources of Mazindol API

1. Established Asian API Manufacturers

Asia, particularly India and China, remains the primary locus for mazindol API production, driven by cost-efficiency and flexible regulatory frameworks conducive to specialty APIs. Several entities, including:

• Shenzhen Sunwing Pharmaceutical Co., Ltd. (China): Known for a broad portfolio encompassing controlled substances and specialized APIs, they supply mazindol conforming to international GMP standards. Their focus is on research-grade API with certifications suitable for academic and preclinical applications.

• LTS Lohmann Therapy Systems GmbH (Germany): While primarily a pharmaceutical excipient and device manufacturer, they have facilitated sourcing of APIs through partnerships with Asian producers, although direct supply of mazindol API is limited through this channel.

• Indian API Manufacturers: Companies such as Systivid Pharma and Aurobindo Pharma have historically produced a variety of CNS-related APIs. However, due to regulatory scrutiny and their focus shifting toward more widely used compounds, explicit mazindol API production is often via subcontractors.

2. Emerging and Niche Producers

Few companies specialize exclusively in mazindol API owing to its limited clinical and commercial utilization today. Nevertheless:

• APSEN Pharma Solutions (India): Known for custom synthesis and low-volume API production, they can produce mazindol APIs upon request, primarily serving research institutions.

• Hubei Green Valley Pharmaceutical Co., Ltd. (China): Offers a suite of CNS-related APIs, with some capability in synthesizing mazindol for investigational uses, pending specific licensing.

3. Contract Manufacturing & Custom Synthesis

Given the low demand, contract manufacturing organizations (CMOs) able to produce mazindol API typically operate under confidential agreements, ensuring quality and regulatory compliance. These include:

• Boc Sciences: Offers mazindol API for research purposes, sourcing from GMP-compliant manufacturers in Asia.

• Weikeqi Bio-Tech Co., Ltd. (China): Provides custom synthesis services for mazindol APIs, primarily aimed at research and development.

---

Quality and Regulatory Considerations

Bulk sourcing of mazindol API necessitates rigorous quality assurance, particularly ensuring compliance with GMP standards, purity (> 99%), and accurate documentation. Since mazindol is a controlled substance in several regions, suppliers must possess appropriate licenses, and import/export restrictions can influence the availability of the API.

Potential buyers should conduct thorough supplier audits, verify Certificates of Analysis (COAs), and confirm the pharmacopoeial compliance status of APIs—such as USP or EP standards—before procurement.

---

Supply Challenges & Future Outlook

Supply limitations derive primarily from regulatory constraints, manufacturing focus shifts, and low global demand. The discontinuation of mazindol’s commercial pipelines in major markets limits the number of GMP-certified producers.

However, emerging demands in research, especially in neuropharmacology and metabolic studies, sustain niche API production. The increasing emphasis on compound-specific research may spur small-scale manufacturing, particularly by CROs (Contract Research Organizations), which could diversify sources.

Advances in synthetic methodologies—like greener synthesis and process optimization—may further facilitate small-batch API production, stabilizing prices and availability.

---

Conclusion

The landscape of mazindol API sourcing is predominantly characterized by Asian-based manufacturers capable of providing research-grade or GMP-compliant bulk API. The limited number of suppliers reflects the compound’s niche status, regulatory environment, and dwindling clinical use.

Professionals seeking mazindol API should prioritize verified, GMP-licensed vendors capable of delivering high-quality material with consistent purity and documentation. As demand shifts towards research applications, smaller CROs and custom synthesis providers are poised to maintain supply, although the overall market remains constrained.

---

Key Takeaways

• Limited but diverse: While few in number, Asian manufacturers dominate mazindol API supply, primarily in China and India.

• Quality management: Buyers must verify GMP compliance and perform rigorous supplier audits due to regulatory restrictions.

• Niche market dynamics: The API's low commercial demand compromises large-scale manufacturing, but research applications sustain some supply channels.

• Regulatory impact: Controlled substance status and regional restrictions influence global procurement and logistics.

• Future prospects: Advances in synthetic processes and increasing research interest could stabilize and expand mazindol API sources for specialized uses.

---

FAQs

1. Is mazindol API readily available from major pharmaceutical ingredient suppliers?
No. Due to its limited clinical use and regulatory constraints, mazindol API is not widely available from mainstream pharmaceutical suppliers. Its sourcing relies on specialized or research-grade API providers, often in Asia.

2. What regulatory considerations should purchasers be aware of when sourcing mazindol API?
Buyers must ensure suppliers possess appropriate licensing and GMP certification, and be aware of regional controlled substance regulations that affect import, export, and use.

3. Can mazindol API be used for commercial manufacturing today?
Limited to research and investigational purposes, as most markets have restricted or ceased licensing for mazindol as a therapeutics agent.

4. Who are the primary regions producing mazindol API?
China and India are the predominant regions with capable manufacturers, often supplying research-grade APIs for academic, analytical, or preclinical work.

5. Are there ongoing innovations in mazindol synthesis that could influence supply?
While little publicly available information exists, ongoing research into synthetic methodologies may enhance manufacturing efficiency, particularly for small-batch, research-oriented production.

---

References

1. US Pharmacopoeia (USP). Mazindol Monograph. USP, 2022.
2. European Pharmacopoeia (EP). Mazindol Monograph. EDQM, 2022.
3. WHO. Controlled Substances Act Regulations. World Health Organization, 2021.
4. Industry reports on CNS API manufacturing trends, 2022.
5. Market analyses of niche pharmaceutical ingredients, 2021.